A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating DCVax(Tm)-Prostate, Autologous Dendritic Cells Loaded With Recombinant PSMA for the Treatment of Metastatic Hormone Refractory Prostate Cancer

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating DCVax(Tm)-Prostate, Autologous Dendritic Cells Loaded With Recombinant PSMA for the Treatment of Metastatic Hormone Refractory Prostate Cancer

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 30 Apr 2013

At a glance

  • Drugs Dendritic cell vaccine-Northwest Biotherapeutics (Primary)
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top